NEW YORK, Dec. 14, 2016 /PRNewswire/ -- A new U.S. Food & Drug Administration (FDA) review has failed to rule out an association between Actos and an increased risk of bladder cancer. While the labels for Actos and other pioglitazone-containing Type 2 diabetes medications already contain warnings regarding this risk, a Drug Safety Communication issued on December 12, 2016 indicates that the agency is updating the labels once again to describe the additional studies it has reviewed.
"Since the FDA initially warned of the potential link between Actos and bladder cancer in 2011, thousands of alleged victims have filed lawsuits seeking compensation for their pain and suffering. We are pleased that the agency is taking steps to further clarify this important public health matter," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm continues to offer free Actos lawsuit evaluations to long-term users of the medication who have been diagnosed with bladder cancer.
Actos and Bladder Cancer
Information regarding a possible increased risk of bladder cancer was first added to the Actos label in June 2011, after interim results from a 10-year study suggested that taking Actos for more than 1 year was associated with a doubling of the risk of bladder cancer. Findings from subsequent research have been mixed, as some studies have indicated a heightened risk while others have not. Overall, however, the data suggests that pioglitazone use may be linked to an increased risk of bladder cancer, the FDA said in in its most recent communication.
Thousands of Actos lawsuits were filed in the wake of the 2011 label update, all of which accused Takeda Pharmaceuticals of concealing data linking the drug to bladder cancer. Many of these claims were centralized in a multidistrict litigation that is still underway in the U.S. District Court, Western District of Louisiana. In April 2015, Takeda agreed to a $2.4 billion Actos settlement that ultimately resolved more than 8,000 such claims. Plaintiffs eligible to participate in the settlement program included individuals who were prescribed a pioglitazone medication, including Actos, ACTOplus Met, ACTOplus Met XR, or Duetact, prior to December 1, 2011, and who were diagnosed with bladder cancer before August 28, 2015. (In re: Actos Product Liability Litigation, MDL No. 2299)
Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP's website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/actos-lawsuit-news-fda-confirms-association-between-actos-and-increased-risk-of-bladder-cancer-bernstein-liebhard-llp-reports-300378445.html
SOURCE Bernstein Liebhard LLP